Vaxart Ownership
| VXRT Stock | USD 0.60 0.01 1.64% |
Shares in Circulation | First Issued 1985-09-30 | Previous Quarter 184.7 M | Current Value 227.5 M | Avarage Shares Outstanding 17.5 M | Quarterly Volatility 44.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Vaxart |
Vaxart Stock Ownership Analysis
About 18.0% of the company outstanding shares are owned by institutional investors. The book value of Vaxart was at this time reported as 0.38. The company recorded a loss per share of 0.4. Vaxart Inc last dividend was issued on the 9th of November 2012. The entity had 1:11 split on the 14th of February 2018. Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California. Vaxart operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. For more information please call Cezar MBA at 650 550 3500 or visit https://vaxart.com.Besides selling stocks to institutional investors, Vaxart also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Vaxart's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Vaxart's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Vaxart Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Vaxart Inc are currently held by insiders. Unlike Vaxart's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Vaxart's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Vaxart's insider trades
Vaxart Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vaxart is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vaxart Inc backward and forwards among themselves. Vaxart's institutional investor refers to the entity that pools money to purchase Vaxart's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Iht Wealth Management, Llc | 2024-06-30 | 234.7 K | Raymond James Finl Svs Advisors, Inc. | 2024-09-30 | 188.4 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 186.6 K | Bank Of America Corp | 2024-06-30 | 166.2 K | Monaco Asset Management | 2024-09-30 | 164.3 K | Qube Research & Technologies | 2024-06-30 | 163.6 K | Charles Schwab Investment Management Inc | 2024-09-30 | 153.5 K | Simplex Trading, Llc | 2024-06-30 | 98.3 K | Group One Trading, Lp | 2024-06-30 | 84.4 K | Sio Capital Management, Llc | 2024-06-30 | 14.8 M | Vanguard Group Inc | 2024-09-30 | 10.1 M |
Vaxart Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaxart insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaxart's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vaxart insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vaxart Outstanding Bonds
Vaxart issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vaxart Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vaxart bonds can be classified according to their maturity, which is the date when Vaxart Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| Vector Group 105 Corp BondUS92240MBJ62 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.